364 JAM-A is over-expressed in aggressive Her2 positive breast cancersdoi:10.1016/s1359-6349(10)71165-4K. BrennanT. RocheE.A. McSherryT. O'GradyE.W. KayA.M. HopkinsElsevier BV
Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We set out to understand the genomics of HER2 ...
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer Prior studies have suggested a higher prevalence of high grade, ER-negative, HER2-positive, and basal-like carcinomas in young women with breast cancer. Ho... L.,C.,Collins,... ...
we examined American Joint Committee on Cancer (AJCC) cancer staging, T-category, N-category, Nottingham pathological grade, subtype, and Pam50 in both the GSE96058 and TCGA cohorts. The score was not associated with aggressive clinical parameters including AJCC stage, and T-category in ...
The HER2-positive breast cancer subtype (HER2+-BC) displays a particularly aggressive behavior. Anti-HER2 therapies have significantly improved the survival of patients with HER2+-BC. However, a large number of patients become refractory to current targeted therapies, necessitating the development of ...
Two trials explored the role of lapatinib (Tykerb) as neoadjuvant therapy in early-stage HER2-positive breast cancer and concluded that its effectiveness is statistically no better than standard trastuzumab (Herceptin) therapy. Investigators said that the adverse events many patients experience ...
Collectively, we firstly defined the oncogenic role of TMED3 in breast cancer showing that elevated TMED3 significantly correlated with inferior overall prognosis as well as ER, PR and HER2 status and that TMED3 can promote proliferation, migration and invasion of breast cancer cells in vitro. Fur...
at SABCS 2020 suggested that high Ki-67 levels in conjunction with high-risk features could be used to select patients who would benefit from the addition of abemaciclib (Verzenio) to endocrine therapy (ET) in the adjuvant treatment of ER-positive, HER2- negative stage I or II breast cancer...
A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they overexpress. These malignancies are typically treated with various ErbB2-targeted drugs, but many such cancers develop resistance to these agents and become incurable. Conceivably, treatment of ErbB2-positive cance...
Immunotherapy, which is now considered as the fourth pillar in cancer treatment, has in OS so far not been more successful10. Different antigens have been targeted by CAR in OS13,14,15,34, the most advanced being anti-HER2 CAR, which was successfully tested in a phase I/II sarcoma ...